SCHEMBL5380356

SCHEMBL5380356

N#CCn1cc(-c2cc(Oc3cccc(N)c3)ncn2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FEN1 P39748 2/20 0.41
PIM1 P11309 2/20 0.37
PIM3 Q86V86 2/20 0.37
PIM2 Q9P1W9 2/20 0.37
ROCK1 Q13464 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
BRCA1 P38398 1/20 0.34
HBB P68871 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
LCK P06239 1/20 0.34
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5342655 0.83 NPC1 (0.47) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL5424683 0.82 PIM1 (0.43) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL5340477 0.80 NPC1 (0.47) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL5339896 0.80 KDR (0.45) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL5452651 0.80 MAPT (0.42) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL5454528 0.79 FGFR1 (0.46) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL5339931 0.78 NPC1 (0.44) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL5430733 0.71 FEN1 (0.40) CYP1A2FEN1PIM1PIM3PIM2
SCHEMBL5429253 0.70 NPC1 (0.44) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL5340118 0.69 MAP2K7 (0.44) NPC1RAB9ACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 NPC1 4325/4885RAB9A 1640/4885CYP1A2 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.